Company profile: HiFiBiO Therapeutics
1.1 - Company Overview
Company description
- Provider of proprietary single-cell technologies for drug and biomarker discovery and development, and biotherapeutic antibody candidates that mobilize the immune system, including targets TNFR2, OX-40, BTLA, Gal-9, CCR8, and CXCR5 for solid tumors, myeloid malignancies, B cell lymphomas, and autoimmune diseases; collaborates through open-innovation partnerships with industry and academia.
Products and services
- HFB301001: A novel OX-40 agonistic antibody, fully human IgG1-class, optimized for enhanced clinical activity in solid tumors, demonstrating superior anti-tumor activity in preclinical models
- HFB200603: An antagonist antibody targeting BTLA to restore anti-tumor immunity, showing synergistic effects with anti-PD-1 and favorable pharmacokinetic profiles in preclinical studies
- HFB200301: A first-in-class agonistic anti-TNFR2 antibody for solid tumors, exhibiting potent antitumor activity and well-tolerated profiles in preclinical studies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to HiFiBiO Therapeutics
Silicon Biosystems
HQ: Italy
Website
- Description: Provider of lab-on-a-chip technologies for miniaturized cell-biology testing, including SmartSlide for enrichment and label-free separation, DEPArray for image-based cell sorting and single-cell isolation, CELLSEARCH tests for circulating tumor cells and multiple myeloma, CellMag products for immunomagnetic enrichment and staining, and Ampli1 kits for single-cell DNA analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Silicon Biosystems company profile →
Afyren
HQ: France
Website
- Description: Provider of biotechnological and green chemistry solutions that valorize non-food biomass into biosourced molecules and natural organic acids. Offers AFYREN NEOXY production facility, FLAVYREN flavor and fragrance acids with a low carbon footprint, and a circular eco approach using organic waste and aiming for zero industrial waste via by-product valorization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Afyren company profile →
Immunophotonics
HQ: United States
Website
- Description: Provider of immunotherapy-based cancer treatments, including IP-001, a proprietary glycan polymer that stimulates immune responses against cancer and infectious diseases by acting as an antigen depot and immune activator; and an Abscopalizing Technique involving IP-001 injection with tumor ablation or radiation to induce a systemic immune response against cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunophotonics company profile →
Beacon Discovery
HQ: United States
Website
- Description: Provider of GPCR-focused drug discovery services from concept to clinic, including over 8,000 assays, target identification, hit finding, lead optimization, mechanistic studies, and preclinical safety and toxicity. Offerings include small molecule support, LeadHunter cell-based assays for GPCRs and orphan GPCRs, phenotypic drug discovery, in vitro safety assays and panels, and ADME assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Beacon Discovery company profile →
NuAire
HQ: United States
Website
- Description: Provider of ergonomic laboratory equipment for Life Science, Clinical, and Industrial research applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NuAire company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for HiFiBiO Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to HiFiBiO Therapeutics
2.2 - Growth funds investing in similar companies to HiFiBiO Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for HiFiBiO Therapeutics
4.2 - Public trading comparable groups for HiFiBiO Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →